We are dedicated to providing your patients with ongoing support to help them start and continue taking ORGOVYX as prescribed. We know how important it is for patients to stay on track while on treatment. We’re here to help.
We can help assist your patients with access challenges. This includes benefits investigation on patients' insurance coverage, prior authorization assistance through CoverMyMeds®, and appeals support.
Eligible patients who are new to ORGOVYX can get up to a 2-month supply of medication at no cost.
Eligible commercially insured patients who are experiencing coverage issues can receive ORGOVYX at no cost for a limited period of time.
We offer options to help your eligible patients afford their treatment, including copay assistance for commercially insured patients for as little as $10 per month.
We are here to support your enrolled patients with check-in calls to help answer their questions about treatment.
We provide educational resources to help support your patients throughout their treatment.
Log in to your CoverMyMeds® account and submit the ORGOVYX Support Program Start Form online
The CoverMyMeds portal allows pharmacists and providers to initiate, transmit, and track the status of prior authorization (PA) requests and to enroll in the ORGOVYX Support Program. The CoverMyMeds portal helps with:
Print and fax the completed ORGOVYX Support Program Start Form to 1-844-826-8875
For more information, call 1-833-ORGOVYX (1-833-674-6899)
CoverMyMeds is a registered trademark of CoverMyMeds LLC.
ORGOVYX Support Program is not a CoverMyMeds LLC program or solution. ORGOVYX Support Program is owned and operated solely by Myovant Sciences.
The ORGOVYX Free Trial Program is designed to help your eligible patients get started on ORGOVYX. Patients who have not previously been prescribed ORGOVYX can get up to a 2-month supply at no cost. Patients must meet the program eligibility requirements.
*The ORGOVYX Free Trial Program (FTP) provides an up to 2-month supply of ORGOVYX at no cost to patients who meet FTP eligibility requirements and who agree to the FTP terms and conditions by submitting a signed FTP enrollment form. (i) FTP is a free trial offer, intended solely to allow new patients to try ORGOVYX and to determine with their healthcare provider whether ORGOVYX is right for them. There is no obligation to continue use of ORGOVYX after the free trial has been completed; (ii) to be eligible, patient must: (1) reside in the United States or Puerto Rico and (2) be a new patient not currently using ORGOVYX or who previously received ORGOVYX through the FTP; (iii) ORGOVYX supplied through the FTP will be dispensed only through a pharmacy designated by Myovant Sciences up to the limits above; (iv) product may only be delivered to the patient’s home address (no P.O. boxes) or the prescribing healthcare provider’s office; (v) it is unlawful for any person to sell, purchase, trade, barter or export ORGOVYX supplied through the FTP or make an offer to do so; (vi) ORGOVYX supplied through the FTP may not be billed (in whole or part, directly or indirectly) to any patient or third-party payer, including Medicare, Medicaid and commercial insurance plans; (vii) Myovant Sciences reserves the right to change or discontinue the FTP at any time without notice; (viii) the FTP is not health insurance; (ix) the FTP is not a discount, rebate, coupon, cost-sharing program or other form of financial assistance and no portion of the value of the FTP product may count as a patient out-of-pocket expense under any health insurance program; (x) ORGOVYX supplied free of charge through the FTP is not contingent on continued use of ORGOVYX. To continue a patient on therapy, a separate prescription must be written by the healthcare provider; (xi) the FTP is void where prohibited by law and where use is prohibited by the patient’s insurance provider.
The ORGOVYX Bridge Program can help commercially insured patients get access to treatment by providing ORGOVYX at no cost if they are:
†The ORGOVYX Bridge Program (“Program”) provides ORGOVYX at no cost for a limited period (up to 4 months) to eligible, commercially-insured patients whose insurance coverage is delayed or who experience a temporary lapse in coverage. This Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government insurance, or any state patient or pharmaceutical assistance program. Prescribers must complete the Bridge prescription on the start form. By participating, patient acknowledges intent to pursue insurance coverage for ORGOVYX with their health care provider. Program requires the submission of a request for coverage within 9 months post-Program initiation in order to remain eligible. Patients will receive their maintenance drug supply each month for up to 12 months or until they receive insurance coverage approval, whichever occurs earlier. Program is not available to patients who are uninsured or where prohibited by law. Patients may be asked to reverify insurance coverage status during the course of the Program. Patient and participating prescribers agree not to seek reimbursement for all or any part of the benefit received by the patient through this Program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Other limitations may apply. Myovant Sciences reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.
Pay as little as $10 per month
With the ORGOVYX Copay Assistance Program, eligible commercially insured patients pay as little as $10 per month.‡ Learn more about the eligibility criteria for the ORGOVYX Copay Assistance Program by calling 1-833-ORGOVYX (1-833-674-6899).
This is a third-party website not controlled by Myovant Sciences.
‡The ORGOVYX Copay Assistance Program (“Program”) is for eligible patients with commercial prescription insurance for ORGOVYX. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patient must be a resident of the U.S., Puerto Rico, or U.S. Territories. This Program is void where prohibited by state law. Certain rules and restrictions apply. This card is not insurance. This offer cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer. Patient and participating pharmacists agree not to seek reimbursement for all or any part of the benefit received by the patient through this Program. Patient and participating pharmacists agree to report the receipt of Program benefits to any insurer or other third party who pays for or reimburses any part of the prescription filled using the Card, as may be required by such insurer or third party. Myovant reserves the right to revoke, rescind, or amend this offer without notice. The Program has no control over the decisions made by, and does not guarantee support from, independent third parties.
For eligible uninsured patients
Through the Myovant Patient Assistance Program, eligible patients may be able to get ORGOVYX at no cost. Learn more about the eligibility criteria for the Myovant Patient Assistance Program by calling 1-833-ORGOVYX (1-833-674-6899).
For Medicare Part D PATIENTS
Your patients may qualify for additional financial support resources. Learn more by calling 1-833-ORGOVYX (1-833-674-6899).
ORGOVYX is supplied in a bottle containing 30 tablets that are 120 mg each (NDC: 72974-120-01).
ORGOVYX is available to in-office dispensing pharmacies and hospital/academic/institutional specialty pharmacies. ORGOVYX can only be ordered through the authorized specialty distributors below:
Cardinal Health Specialty Distribution
Standard Ordering Hours: Monday-Friday 9 AM–7 PM ET
We have selected 2 URAC and ACHC accredited mail-order specialty pharmacies to provide service nationally to your patients.
These specialty pharmacies can also provide information and resources to your patients, including free delivery, 24-hour access to a pharmacist, ORGOVYX medication counseling, and adherence support.
Biologics by McKesson
Standard Ordering Hours: Monday-Friday 8 AM-8 PM ET
Clinicians are available to speak with patients 24 hours a day, every day.
Standard Ordering Hours: Monday-Friday 8 AM-8 PM ET
Clinicians are available to speak with patients 24 hours a day, every day.
ACHC=Accreditation Commission for Health Care; URAC=Utilization Review Accreditation Commission.
Myovant Sciences isn't affiliated nor does it recommend the use of any of the listed pharmacies or distributors. It is in the prescriber's discretion to select the appropriate pharmacy or distributor for their specific needs.
ORGOVYX SUPPORT PROGRAM PATIENT START FORM Download PDF
ORGOVYX SUPPORT PROGRAM Free Trial Form Download PDF
ORGOVYX SUPPORT PROGRAM PATIENT Consent Form Download PDF
Sample Letter of Medical Necessity template Download Word Document
SAMPLE LETTER OF MEDICAL NECESSITY CHECKLIST Download PDF
Sample Letter of appeals Download Word Document
SAMPLE LETTER OF APPEALS CHECKLIST Download PDF
QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.
Embryo-Fetal Toxicity: The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX
Laboratory Testing: Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.
Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in ≥0.5% of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX.
Most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) in patients receiving ORGOVYX were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (27%), fatigue (26%), aspartate aminotransferase increased (18%), constipation (12%), and diarrhea (12%).
Co-administration of ORGOVYX with a P-gp inhibitor increases the area under the curve (AUC) and maximum concentration (Cmax) of ORGOVYX, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first, separate dosing by at least 6 hours, and monitor patients more frequently for adverse reactions. Treatment with ORGOVYX may be interrupted for up to 2 weeks for a short course of treatment with certain P-gp inhibitors. If treatment with ORGOVYX is interrupted for more than 7 days, resume administration of ORGOVYX with a 360 mg loading dose on the first day, followed by 120 mg once daily.
Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases the AUC and Cmax of ORGOVYX, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily.
ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
Please see full Prescribing Information for ORGOVYX.
The information contained in this website is intended for US healthcare professionals only.
Are you a US healthcare professional?Yes No
You are about to leave
The website you are linking to is neither owned nor controlled by Myovant Sciences GmbH.
Myovant Sciences GmbH is not responsible for the content or services on the site.
Your information has been received.
We have received your request for more information about ORGOVYX™ (relugolix). A Myovant Sciences representative in your area will follow up soon to get you the information you need.